Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

NCT02098239 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Jaundice
Pancreatic Cancer

Interventions

DRUG: G17DT

Sponsor

Cancer Advances Inc.